Q-omics provides the consensus-scored VN1R78P profile across patient tissues and cancer cell-line models. VN1R78P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, VN1R78P is differentially expressed in 4, with the highest sampling consensus in LIHC. Additionally, VN1R78P RNA expression shows 6,701 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, LIHC, and STAD as cancer lineages where VN1R78P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VN1R78P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VN1R78P survival associations across molecular data types. VN1R78P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VN1R78P RNA expression–survival associations across cancer types. High VN1R78P expression shows unfavorable associations in COAD, BRCA, READ, UCS and LGG, but favorable associations in LUAD. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for VN1R78P RNA expression.
This table summarizes VN1R78P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for VN1R78P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VN1R78P shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC and KIRC. The LIHC box plot shows higher VN1R78P RNA expression in tumor versus normal tissue (log2 FC = +0.072, t-test p = .012).
This table shows molecular features associated with VN1R78P in patient tissues and cancer cell lines. In patient samples, VN1R78P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
